Pharmaceutical News

RSS

Scientists develop technique to predict new target diseases for existing drugs

Scientists at the University of North Carolina at Chapel Hill School of Medicine and the University of California, San Francisco have developed and experimentally tested a technique to predict new target diseases for existing drugs.

4 Nov 2009

Study results of nucleoside polymerase and protease inhibitor combination therapy for HCV promising

All approved therapy regimens to treat patients with hepatitis C are based on interferon, which must be injected. In this clinical trial to be presented at the annual meeting of the American Association for the Study of Liver Diseases, researchers treated patients - both treatment naive and experienced patients - with a twice daily oral combination therapy of a nucleoside polymerase and protease inhibitor.

4 Nov 2009

Takeda Pharmaceuticals strengthens its North American market

Takeda Pharmaceuticals North America, Inc., today announced the incorporation of Takeda Pharmaceuticals Mexico, S.A. de C.V. This expansion strengthens the company's North American presence, bolstering existing operations in the United States and Canada. Takeda Pharmaceuticals Mexico will be headquartered in Mexico City.

4 Nov 2009

Survey shows majority of rheumatologists would prescribe Actemra drug for rheumatoid arthritis

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 98 percent of surveyed rheumatologists indicate they will prescribe Roche's Actemra, an interleukin-6 inhibitor, for the treatment of rheumatoid arthritis following the agent's expected launch in 2010.

4 Nov 2009

Canadian patients have less access to the latest medicines, says report

Canadian patients have less access to the latest medicines when compared to the world's developed countries, concludes a comprehensive new report released today. The Report shows Canada ranks 20th out of 25 OECD countries in public reimbursement of new drug therapies. Canada's grade of 56% is comparable with Iceland, Slovakia and Turkey.

4 Nov 2009

Predictive Biosciences commences clinical trials of its bladder cancer assay

Predictive Biosciences Inc. today announced the publication of pilot study results in the November issue of the Journal of Urology, highlighting the Company’s novel urinary biomarker approach to bladder cancer detection that achieves exceptionally high Negative and Positive Predictive Values (NPV and PPV).

4 Nov 2009

MagForce Nanotechnologies completes clinical trial of Nano-Cancer therapy in glioblastoma patients

MagForce Nanotechnologies AG has successfully completed its single-arm clinical trial on the efficacy of thermotherapy using superparamagnetic nanoparticles in patients with recurrent glioblastoma.

4 Nov 2009

Report: Pandemic flu threat influences vaccine market to expand rapidly

MarketResearch.com has announced the addition of Datamonitor's new report "Seasonal Influenza Vaccines Market Forecast," to their collection of Healthcare market reports.

4 Nov 2009

Teva Pharmaceutical launches Fexofenadine HCl and Pseudoephedrine HCl tablets

Teva Pharmaceutical Industries Ltd. announced today the commercial launch of Fexofenadine Hydrochloride 60 mg and Pseudoephedrine Hydrochloride 120 mg Extended-Release Tablets, the same as the sanofi-aventis U.S. allergy treatment Allegra-D® 12 Hour (fexofenadine HCl 60 mg and pseudoephedrine HCl 120 mg) Extended-Release Tablets. Teva's product is an alternative to the brand product, which had annual sales of approximately $293 million in the United States for the twelve months that ended June 30, 2009, based on IMS sales data.

4 Nov 2009

H1N1 vaccine: Discussions and debates

You can't avoid H1N1 media coverage. It's front-page news on the web, the presses, the airways. Vaccine details, or lack of, are spurring discussion and debate. And a lot of people are in a quandary about whether or not to have the H1N1 shot based on their personal views and the information disseminated for public knowledge.

4 Nov 2009

U.S. clinical trials show single dose of H1N1 vaccine protects pregnant women, children under 10 need two doses

U.S. government data released on Monday confirmed that a single dose of the vaccine protects pregnant women from the virus, while children under the age of 10 years need two doses of the vaccine, the Washington Post reports. The findings came the same day that a team of experts tasked with monitoring the national H1N1 vaccine campaign for any adverse side effects met for the first time.

4 Nov 2009

Department of Health: CDC has allocated 964,100 doses of H1N1 vaccine to Pennsylvania to date

The federal Centers for Disease Control and Prevention, or CDC, has allocated a total of 964,100 doses of H1N1 vaccine to Pennsylvania to date, the state Department of Health announced today.

4 Nov 2009

Common pain killers may blunt the effect of flu shots

With flu vaccination season in full swing, research from the University of Rochester Medical Center cautions that use of many common pain killers - Advil, Tylenol, aspirin - at the time of injection may blunt the effect of the shot and have a negative effect on the immune system.

4 Nov 2009

Lovastatin-synthesizing enzyme successfully reconstituted

Researchers from the UCLA Henry Samueli School of Engineering and Applied Science have for the first time successfully reconstituted in the laboratory the enzyme responsible for producing the blockbuster cholesterol-lowering drug lovastatin.

4 Nov 2009

EntreMed to present its Aurora A/angiogenic kinase inhibitor data at the AACR-NCI-EORTC conference

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced presentations for its Aurora A/angiogenic kinase inhibitor, ENMD-2076, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held November 15-19, 2009 in Boston, Massachusetts. Presentations are listed below.

3 Nov 2009

Acorda Therapeutics' financial results for the third quarter of 2009 and update on Fampridine-SR

Acorda Therapeutics, Inc. today announced its financial results for the third quarter of 2009.

3 Nov 2009

Schering-Plough to donate $200,000 and vaccine for rabies-control projects in India

Schering-Plough Corporation today announced it has initiated sponsorship of two projects in India to reduce the incidence of human and animal rabies through improved educational awareness and mass vaccination of dogs. The company will donate $200,000 and rabies vaccine from Intervet/Schering-Plough as well as share expertise with partners to support successful implementation of the projects in ten villages surrounding Bangalore and Pune, India.

3 Nov 2009

AMRI receives $750,000 milestone payment from Bristol-Myers Squibb

AMRI announced today that a third compound being developed under its license and research agreement with Bristol-Myers Squibb Company will proceed into preclinical development. AMRI will receive a $750,000 payment from Bristol-Myers Squibb for the completion of this milestone, marking the fifth milestone payment in the ongoing research collaboration between the two companies.

3 Nov 2009

Macomb County Health Department announces H1N1 influenza clinic

Another large community H1N1 influenza clinic has been scheduled by the Macomb County Health Department, the department announced today. It will be held at Freedom Hill County Park in Sterling Heights this Saturday, Nov. 7, from 9 a.m. to 3 p.m. Freedom Hill is located at 14900 Metropolitan Parkway.

3 Nov 2009

Prasco Laboratories to provide distribution services for generic versions of Allegra-D and Drisdol

Prasco Laboratories announced today that it has entered into agreements with Winthrop U.S., a business of sanofi-aventis U.S., to provide sales support and distribution services to Winthrop U.S. for authorized generic versions of Allegra-D® 12 Hour (fexofenadine HCl 60 mg and pseudoephedrine HCl 120 mg) extended-release tablets and Drisdol® (ergocalciferol) capsules in the United States under the Winthrop label.

3 Nov 2009

Pharmaceutical News

Scientists develop technique to predict new target diseases for existing drugs

Study results of nucleoside polymerase and protease inhibitor combination therapy for HCV promising

Takeda Pharmaceuticals strengthens its North American market

Survey shows majority of rheumatologists would prescribe Actemra drug for rheumatoid arthritis

Canadian patients have less access to the latest medicines, says report

Predictive Biosciences commences clinical trials of its bladder cancer assay

MagForce Nanotechnologies completes clinical trial of Nano-Cancer therapy in glioblastoma patients

Report: Pandemic flu threat influences vaccine market to expand rapidly

Teva Pharmaceutical launches Fexofenadine HCl and Pseudoephedrine HCl tablets

H1N1 vaccine: Discussions and debates

U.S. clinical trials show single dose of H1N1 vaccine protects pregnant women, children under 10 need two doses

Department of Health: CDC has allocated 964,100 doses of H1N1 vaccine to Pennsylvania to date

Common pain killers may blunt the effect of flu shots

Lovastatin-synthesizing enzyme successfully reconstituted

EntreMed to present its Aurora A/angiogenic kinase inhibitor data at the AACR-NCI-EORTC conference

Acorda Therapeutics' financial results for the third quarter of 2009 and update on Fampridine-SR

Schering-Plough to donate $200,000 and vaccine for rabies-control projects in India

AMRI receives $750,000 milestone payment from Bristol-Myers Squibb

Macomb County Health Department announces H1N1 influenza clinic

Prasco Laboratories to provide distribution services for generic versions of Allegra-D and Drisdol

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News